Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal

References

• Armitage JO. Treatment of non-Hodgkin’s lymphoma. N. Engl. J. Med. 328(14), 1023–1030, (1993).
   PubMed Web of Science ®Google Scholar
• Jamal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8–29 (2004).
   PubMedGoogle Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J. Clin. Oncol. 16(8), 2789–2795 (1998).
   Google Scholar
• Peterson BA, Petroni GR, Frizzera G et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J. Clin. Oncol. 21(1), 5–15 (2003).
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 339(1), 21–26 (1998).
   PubMed Web of Science ®Google Scholar
• Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr. Hematol. Rep. 4(1), 7–14 (2005).
   PubMedGoogle Scholar
• Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B-cell antigens: CD20. In: Leukocyte Typing IV: White Cell Differentiation Antigens. Knapp W, Dorkey B, Gilks WR et al. (Eds), Oxford University Press, Oxford, UK, 46–48 (1989).
   Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140–174 (2005).
   PubMedGoogle Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103(7), 2738–2743 (2004).
   PubMed Web of Science ®Google Scholar
• Du Y, Honeychurch J, Cragg MS et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103(4), 1485–1494 (2004).
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329(17), 1219–1224 (1993).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with 131I-anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329(7), 459–465 (1993).
   PubMed Web of Science ®Google Scholar
• Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2(3), 457–470 (1996).
   PubMed Web of Science ®Google Scholar
• Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin’s lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 59(5), 1274–1287 (2004).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-López AJ, White CA et al. rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135–3143 (2000).
   PubMedGoogle Scholar
• Piro LD, White CA, Grillo-López AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann. Oncol. 10, 655–661 (1999).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technol. Assess. 8(37), iii, ix-xi, 1–82 (2004).
   Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 22(23), 4659–4664 (2004).
   Google Scholar
• Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin. Proc. 78(11), 1340–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 8, 175–192 (2005).
   PubMedGoogle Scholar
• Looney RJ, Anolik J, Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr. Dir. Autoimmun. 8, 193–205 (2005).
   PubMedGoogle Scholar
• Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40(9), 3147–3154 (1980).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol. 2(8), 881–891 (1984).
   PubMed Web of Science ®Google Scholar
• Foon KA, Schroff RW, Bunn PA et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukaemia. Blood 64, 1085–1093 (1984).
   PubMed Web of Science ®Google Scholar
• DeNardo SJ, DeNardo GL, O’Grady LF et al. Treatment of B-cell malignancies with 131I Lym-1 monoclonal antibodies. Int. J. Cancer Suppl. 3, 96–101 (1988).
   PubMedGoogle Scholar
• Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol. Immunother. 43(1), 26–30 (1996).
   PubMed Web of Science ®Google Scholar
• Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin. Oncol. 30(4), 465–475 (2003).
   PubMed Web of Science ®Google Scholar
• Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol. Immunother. 52(5), 281–296 (2003).
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Badger CC et al. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol. 7(8), 1027–1038 (1989).
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Horowitz JA, Sharkey RM et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol. 9(4), 548–564 (1991).
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt’s lymphoma xenografts. Cancer Res. 52(23), 6476–6481 (1992).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8), 2457–2466 (1994).
   PubMed Web of Science ®Google Scholar
• Hohenstein MA, Augustine SC, Rutar F, Vose JM. Establishing an institutional model for the administration of tositumomab and iodine I131 tositumomab. Semin. Oncol. 30(2 Suppl.4), 39–49 (2003).
   PubMedGoogle Scholar
• Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkin’s lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat. Rev. 30(2), 165–172 (2004).
   PubMed Web of Science ®Google Scholar
• Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol. 39(1–2), 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin’s lymphoma. Drugs Today (Barc.) 40(2), 111–119 (2004).
   PubMed Web of Science ®Google Scholar
• Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC. Radioimmunotherapy of non-Hodgkin’s lymphoma: clinical development of the Zevalin regimen. Biotechnol. Ann. Rev. 10, 265–295 (2004).
   PubMedGoogle Scholar
• Micallef IN. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin’s lymphoma. Clin. Lymphoma 5(Suppl. 1), S27–S32 (2004).
   Google Scholar
• Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J. Clin. Oncol. 19(19), 3918–3928 (2001).
   PubMed Web of Science ®Google Scholar
• Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin’s lymphoma. Oncologist 9(2), 160–172 (2004).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmuno conjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma. Expert Rev. Anticancer Ther. 4(1), 18–26 (2004).
   PubMedGoogle Scholar
• Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr. Hematol. Rep. 4(1), 7–14 (2005).
   PubMedGoogle Scholar
• Koral KF, Dewaraja Y, Clarke LA et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin’s lymphoma: preliminary report. Cancer Biother. Radiopharm. 15, 347–355 (2000).
   PubMed Web of Science ®Google Scholar
• Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J. Nucl. Med. 44, 1541–1543 (2003).
   PubMedGoogle Scholar
• Sgouros G, Squeri S, Ballangrud AM et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J. Nucl. Med. 44, 260–268 (2003).
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Brenner A, Burton J et al. Radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-DOTA humanized antiCD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J. Nucl. Med. 44, 2000–2018 (2003).
   PubMed Web of Science ®Google Scholar
• Vose JM, Colcher D, Gobar L et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin’s lymphoma. Leuk. Lymphoma 38(1–2), 91–101 (2000).
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46(1–3), 149–168 (2001).
   PubMed Web of Science ®Google Scholar
• Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 31(7), 1191–1198 (1990).
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46(Suppl. 1), S115–S127 (2005).
   PubMed Web of Science ®Google Scholar
• Esteban JM, Schlom J, Mornex F, Colcher D. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur. J. Cancer Clin. Oncol. 23(6), 643–655 (1987).
   PubMedGoogle Scholar
• Sparks RB, Crowe EA, Wong FC, Toohey RE, Siegel JA. Radiation dose distributions in normal tissue adjacent to tumors containing 131I or 90Y: the potential for toxicity. J. Nucl. Med. 43(8), 1110–1114 (2002).
   PubMedGoogle Scholar
• Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 94(4 Suppl.), 1215–1223 (2002).
   PubMedGoogle Scholar
• Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 20(10), 2453–2463 (2002).
   PubMed Web of Science ®Google Scholar
• Davis TA, Kaminski MS, Leonard JP et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. 10(23), 7792–7798 (2004).
   PubMed Web of Science ®Google Scholar
• DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit. Rev. Oncol. Hematol. 39, 203–218 (2001).
   PubMedGoogle Scholar
• Siegel JA, Yeldell D, Goldenberg DM et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J. Nucl. Med. 44(1), 67–76 (2003).
   PubMedGoogle Scholar
• Wessels BW, Bolch WE, Bouchet LG et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multi-institutional comparison. J. Nucl. Med. 45(10), 1725–1733 (2004).
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother. Radiopharm. 18, 253–258 (2003).
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Kornmehl E, Leigh B et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J. Nucl. Med. 44, 465–474 (2003).
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Radioimmunotherapy for non-Hodgkin’s lymphoma. Clin. Cancer Res. 10(23), 7789–7791 (2004).
   PubMedGoogle Scholar
• Gordon LI, Molina A, Witzig T et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a Phase 1/2 study. Blood 103(12), 4429–4431 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon LI, Witzig T, Molina A et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma 5(2), 98–101 (2004).
   PubMedGoogle Scholar
• Ansell SM, Schilder RJ, Pieslor PC et al. Antilymphoma treatments given subsequent to yttrium-90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin’s lymphoma: a review of the literature. Clin. Lymphoma 5, 202–204 (2004).
   PubMedGoogle Scholar
• Gregory SA, Leonard JP, Knox SJ, Zelenetz AD, Armitage J, Kaminski M. The iodine I-131 tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/refractory low-grade and transformed low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol. 22, S14 (2004).
   Google Scholar
• Kaminski M, Estes J, Tuck M et al. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma. Proc. Am. Soc. Clin. Oncol. 19, 5a (2000).
   Google Scholar
• Kaminski M, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352, 441–449 (2005).
   PubMed Web of Science ®Google Scholar
• Connors JM. Radioimmunotherapy – hot new treatment for lymphoma. N. Engl. J. Med. 352, 496–498 (2005).
   PubMedGoogle Scholar
• Mones J, Coleman M, Kostakoglu L et al. A dose-escalation study of tositumomab and iodine-131-tositumomab (Bexxar) in patients with previously treated non-Hodgkin’s lymphoma with >25% bone marrow involvement. J. Clin. Oncol. 22, S14 (2004).
   Google Scholar
• Gopal AK, Rajendran JG, Petersdorf SH et al. High dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99(9), 3158–3162 (2002).
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Gooley T et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphoma. Blood 96(9), 2934–2942 (2000).
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM et al. A Phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Southwest Oncology Group Protocol S9911. Blood 102(5), 1606–1612 (2003).
   PubMed Web of Science ®Google Scholar
• Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for cancer: a Minnie Pearl Cancer Research Network Phase II trial. J. Clin. Oncol. 22, S14 (2004).
   PubMedGoogle Scholar
• Link B, Kaminiski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma. J. Clin. Oncol. 22, S14 (2004).
   Google Scholar
• Leonard JP, Coleman M, Kostakagulu L et al. Durable remissions from fludarabine followed by the iodine-I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin’s lymphoma. J. Clin. Oncol. 22, S14 (2004).
   PubMedGoogle Scholar
• Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96, 1259–1266 (2000).
   PubMed Web of Science ®Google Scholar
• Wahl RL, Zasadny KR, Estes J et al. Single center experience with iodine tositumomab radioimmunotherapy for previously untreated follicular lymphoma. J. Nucl. Med. 41(Suppl.), S79 (2000).
   Google Scholar
• Stein R, Qu Z, Chen S et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized antiCD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin. Cancer Res. 10, 2868–2878 (2004).
   PubMedGoogle Scholar
• Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793–1800 (2004).
   PubMed Web of Science ®Google Scholar
• Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin’s lymphoma: a Phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother. Radiopharm. 18, 513–524 (2003).
   PubMed Web of Science ®Google Scholar
• Lindén O, Tennvall J, Cavallin-Ståhl E et al. Radioimmunotherapy using 131I-labeled antiCD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin. Cancer Res. 5(10 Suppl.), S3287–S3291 (1999).
   PubMed Web of Science ®Google Scholar
• Postema EJ, Raemaekers JM, Oyen WJ et al. Final results of a Phase I radioimmunotherapy trial using 186Re-epratuzumab for the treatment of patients with non-Hodgkin’s lymphoma. Clin. Cancer Res. 9(10 Pt 2), S3995–S4002 (2003).
   Google Scholar
• Chatal JF, Harousseau JL, Trümper LH et al. Radioimmunotherapy in non-Hodgkin’s lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized antiCD22 monoclonal antibody, epratuzumab. Cancer Biother. Radiopharm. 19(4), 525 (2004).
   Google Scholar
• Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. 10(16), 5327–5334 (2004).
   PubMed Web of Science ®Google Scholar
• Waldmann T. ABCs of radioisotopes used for radioimmunotherapy: α- and β-emitters. Leuk. Lymphoma 44(Suppl. 3), S107–S113 (2003).
   Google Scholar
• Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. Adv. Pharmacol. 51, 185–208 (2004).
   PubMedGoogle Scholar
• Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol. Biol. 248, 209–225 (2004).
   PubMedGoogle Scholar
• Souriau C, Hudson PJ. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. 3, 305–318 (2003).
   PubMed Web of Science ®Google Scholar
• Chang CH, Sharkey RM, Rossi EA et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther. 1(7), 553–563 (2002).
   PubMed Web of Science ®Google Scholar
• Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 44(3), 400–411 (2003).
   PubMed Web of Science ®Google Scholar
• Rossi EA, Sharkey RM, McBride W et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin. Cancer Res. 9, S3886–S3896 (2003).
   PubMed Web of Science ®Google Scholar
• Axworthy DB, Reno JM, Hylarides MD et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl Acad. Sci. USA 97, 1802–1807 (2000).
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Richel H et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin. Cancer Res. 9, S3897–S3913 (2003).
   PubMed Web of Science ®Google Scholar
• Press OW, Corcoran M, Subbiah K et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98, 2535–2543 (2001).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL). Crit. Rev. Oncol. Hematol. 40, 37–51 (2002).
   Google Scholar
• Forero A, Weiden PL, Vose JM et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104, 227–236 (2004).
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Chang C-H, McBride WJ, Horak ID, Goldenberg DM. Improved therapy of non-Hodgkin’s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia (2005) (In Press).
   PubMedGoogle Scholar
• Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 103(8), 1044–1051 (2005).
   Google Scholar
• Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J. Biopharm. Stat. 14(1), 111–124 (2004).
   PubMedGoogle Scholar
• Jelinek DF, Darce JR. Human B-lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr. Dir. Autoimmun. 8, 266–288 (2005).
   PubMedGoogle Scholar